MERCK 2007 Annual Review » A Robust Pipeline

Merck’s research pipeline continues to grow as we accelerate our discovery efforts. In the past year, we have advanced 26 candidates to the next clinical development stage. We currently have seven candidates in Phase III development, 17 distinct candidates in Phase II and another 23 in Phase I.

Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations.

Advanced Since February 2007
† Clinical program conducted by Allergan, Inc.
* Proof-of-Concept Molecule

Download full pipeline as PDF Phase I & Phase II| Phase III & Beyond

Phase I ⁽¹⁾
Phase II ⁽¹⁾

⁽¹⁾ Candidates shown in Phase I and Phase II include the most advanced candidate for a specific mechanism within a given therapeutic area. Back-up candidates, regardless of their phase of development; additional indications in the same therapeutic area; and additional claims, line extensions or formulations for in-line products are not shown.

2007 Annual Review

A Robust Pipeline

Updated February 15, 2008

Phase I (1)

Phase II (1)

Phase I ⁽¹⁾

Phase II ⁽¹⁾